These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1052 related articles for article (PubMed ID: 17310340)

  • 1. Costs and quality of life of multiple sclerosis in Spain.
    Kobelt G; Berg J; Lindgren P; Izquierdo G; Sánchez-Soliño O; Pérez-Miranda J; Casado MA;
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S65-74. PubMed ID: 17310340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs and quality of life in multiple sclerosis in The Netherlands.
    Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJ; Polman C; Uitdehaag B
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S55-64. PubMed ID: 17310343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs and quality of life for patients with multiple sclerosis in Belgium.
    Kobelt G
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S24-33. PubMed ID: 17318662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs and quality of life of multiple sclerosis in Italy.
    Kobelt G; Berg J; Lindgren P; Battaglia M; Lucioni C; Uccelli A
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S45-54. PubMed ID: 17310336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs and quality of life of multiple sclerosis in Austria.
    Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S14-23. PubMed ID: 17310339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs and quality of life of multiple sclerosis in Germany.
    Kobelt G; Berg J; Lindgren P; Elias WG; Flachenecker P; Freidel M; König N; Limmroth V; Straube E
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S34-44. PubMed ID: 17310337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs and quality of life of multiple sclerosis in Switzerland.
    Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costs and quality of life of multiple sclerosis in Sweden.
    Berg J; Lindgren P; Fredrikson S; Kobelt G
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S75-85. PubMed ID: 17310342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs and quality of life of multiple sclerosis in the United Kingdom.
    Kobelt G; Berg J; Lindgren P; Kerrigan J; Russell N; Nixon R
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S96-104. PubMed ID: 17310341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis.
    Kobelt G; Berg J; Lindgren P; Jönsson B
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S5-13. PubMed ID: 17310344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions.
    Kobelt G; Texier-Richard B; Lindgren P
    Mult Scler; 2009 Jun; 15(6):741-51. PubMed ID: 19383645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs and quality of life of patients with ankylosing spondylitis in Canada.
    Kobelt G; Andlin-Sobocki P; Maksymowych WP
    J Rheumatol; 2006 Feb; 33(2):289-95. PubMed ID: 16465660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-cultural adaptation and validation of multiple sclerosis quality of life questionnaire (MSQOL-54) in a Turkish multiple sclerosis sample.
    Idiman E; Uzunel F; Ozakbas S; Yozbatiran N; Oguz M; Callioglu B; Gokce N; Bahar Z
    J Neurol Sci; 2006 Jan; 240(1-2):77-80. PubMed ID: 16277993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).
    Kobelt G; Andlin-Sobocki P; Brophy S; Jönsson L; Calin A; Braun J
    Rheumatology (Oxford); 2004 Sep; 43(9):1158-66. PubMed ID: 15226514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States.
    Kobelt G; Berg J; Atherly D; Hadjimichael O
    Neurology; 2006 Jun; 66(11):1696-702. PubMed ID: 16769943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An approach to estimating the intangible costs of multiple sclerosis according to disability in Catalonia, Spain.
    Casado V; Romero L; Gubieras L; Alonso L; Moral E; Martinez-Yelamos S; Martinez-Yelamos A; Carmona O; Arbizu T
    Mult Scler; 2007 Jul; 13(6):800-4. PubMed ID: 17613609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Burden of illness in multiple sclerosis (DEFENSE) study: the costs and quality-of-life of Finnish patients with multiple sclerosis.
    Ruutiainen J; Viita AM; Hahl J; Sundell J; Nissinen H
    J Med Econ; 2016; 19(1):21-33. PubMed ID: 26360615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis.
    Kobelt G; Lindgren P; Lindroth Y; Jacobson L; Eberhardt K
    Rheumatology (Oxford); 2005 Sep; 44(9):1169-75. PubMed ID: 15956093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment experience, burden, and unmet needs (TRIBUNE) in Multiple Sclerosis study: the costs and utilities of MS patients in The Netherlands.
    Karampampa K; Gustavsson A; van Munster ET; Hupperts RM; Sanders EA; Mostert J; Sinnige OL; de Graaf J; Pop P; Miltenburger C; Groot MT; Relleke M; van der Hel WS
    J Med Econ; 2013 Jul; 16(7):939-50. PubMed ID: 23692584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries.
    Karampampa K; Gustavsson A; Miltenburger C; Eckert B
    Mult Scler; 2012 Jun; 18(2 Suppl):7-15. PubMed ID: 22623122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.